title: Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
abstract: Talin-1 functions to regulate cell-cell adhesion, and its altered expression was reported to be associated with human carcinogenesis.A total of 280 tissue specimens from prostate cancer (PCa) patients who underwent radical prostatectomy, 75 cases of benign prostatic hyperplasia (BPH) tissue, and 6 cases of normal prostate tissue specimens were collected for construction of tissue microarray and subsequently subjected to immunohistochemical staining of Talin-1 expression.Talin-1 expression was significantly higher in PCa than both normal and BPH tissues (P <0.001). Talin-1 expression in PCa tissues was associated with preoperative prostate-specific antigen (PSA) level, Gleason score, tumor stage, lymph node metastasis, positive surgical margin, extracapsular extension and seminal vesicle invasion (all P <0.05). Logistic regression analysis showed that Talin-1 and Gleason score were independent risk factors for lymph node metastasis of PCa (P <0.001). Receiver operating characteristic (ROC) curve indicated that Talin-1 expression (AUC = 0.766) had a better accuracy to predict PCa lymph node metastasis than Gleason score (AUC = 0.697), whereas their combination could further enhance the prediction accuracy (AUC = 0.803). Kaplan-Meier curve analysis showed that increased Talin-1 expression was associated with shortened biochemical-free survival of PCa patients after radical prostatectomy (P <0.001).These findings suggested that Talin-1 protein was significantly upregulated in PCa tissues compared with that of BPH tissue and Talin-1 expression was an independent predictor for lymph node metastasis and biochemical recurrence of PCa. Further study will investigate the underlying molecular mechanism and the role of Talin-1 in PCa.
authors.affiliation: Department of Urology Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Xu
authors.forename: Hui-Jun
authors.initials: HJ
authors.lastname: Chen
authors.forename: Shao-Hao
authors.initials: SH
authors.lastname: Chen
authors.forename: Xue-Yi
authors.initials: XY
authors.lastname: Xue
authors.forename: Hong
authors.initials: H
authors.lastname: Chen
authors.forename: Qing-Shui
authors.initials: QS
authors.lastname: Zheng
authors.forename: Yong
authors.initials: Y
authors.lastname: Wei
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Li
authors.forename: Jin-Bei
authors.initials: JB
authors.lastname: Huang
authors.forename: Hai
authors.initials: H
authors.lastname: Cai
authors.forename: Xiong-Lin
authors.initials: XL
authors.lastname: Sun
mesh_terms: D000368:Aged; D018572:Disease-Free Survival; D006801:Humans; D008207:Lymphatic Metastasis / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011237:Predictive Value of Tests; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D016608:Talin / Q000235:genetics*; D015854:Up-Regulation / Q000235:genetics*
chemical_list: C518832:TLN1 protein, human; D016608:Talin; D017430:Prostate-Specific Antigen